Compare Invesco DB Commodity Index Tracking Fund (DBC) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco DB Commodity Index Tracking Fund vs State Street SPDR S&P Biotech ETF — how do they compare? Invesco DB Commodity Index Tracking Fund trades at $28.77, while State Street SPDR S&P Biotech ETF trades at $156.06. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Invesco DB Commodity Index Tracking Fund nearer its low. Which is the better fit depends on your goals.
| DBC | XBI | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Broad Market / Factor |
52-Week High | $31.69 | $164.28 |
52-Week Low | $21.62 | $85.16 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DBC, the Invesco DB Commodity Index Tracking ETF, trades at $28.33, up 2.94% today, with a bullish technical signal from moving averages and oscillators. Recent news highlights its role as an inflation hedge, with a 52-week high noted in April 2026. The ETF provides diversified commodity exposure, benefiting from oil supply shocks and safe-haven demand, though key financial ratios like P/E and P/S are not applicable for this fund structure.
Outlook remains positive due to strong momentum and inflation hedging appeal, but risks include commodity price volatility and geopolitical factors. Analyst sentiment is supportive, with the ETF favored in balanced portfolios for moderate-risk investors seeking commodity diversification amid market uncertainty.
XBI trades at $155.34, down 2.32% on the day, but maintains a bullish technical outlook with strong momentum indicators. The biotech ETF has gained significant attention after a 17% monthly surge, driven by sector rotation and M&A activity. Analyst coverage remains limited with a single hold rating, though recent news highlights biotech's strong performance amid market volatility.
The ETF offers exposure to biotech's resurgence with AI drug discovery and deal momentum as catalysts. However, high volatility and concentrated sector risk require careful position sizing. Current technical strength suggests potential for continued upside if sector momentum persists.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Invesco DB Commodity Index Tracking Fund
DBC is a diversified commodity ETF that tracks the DBIQ Optimum Yield Diversified Commodity Index. It invests in futures contracts for 14 heavily traded commodities, including crude oil, gold, and corn, while optimizing for yield and roll costs.
Read more on DBC →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
